Haemonetics Corporation (HAE)

Currency in USD
87.84
+2.82(+3.32%)
Closed·
87.840.00(0.00%)
·

HAE Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
1.14 / 1.09
Revenue / Forecast
339M / 328.92M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/1.27--/342.58M----Free Sign Up
2026/061.14/1.09339.00M/328.92M+4.59%+3.06%Free Sign Up
2026/031.29/1.27346.00M/337.04M+1.57%+2.66%Free Sign Up
2025/121.31/1.25338.97M/331.91M+4.8%+2.13%Free Sign Up
2025/091.27/1.11327.00M/311.46M+14.41%+4.99%Free Sign Up
2025/061.10/1.01321.39M/302.62M+8.91%+6.2%Free Sign Up
2025/031.18/1.22330.60M/330.66M-3.28%-0.02%Free Sign Up
2024/121.19/1.17349.00M/352.98M+1.71%-1.13%Free Sign Up
2024/091.12/1.07346.00M/342.58M+4.67%+1%Free Sign Up
2024/061.02/1.01336.17M/335.08M+0.99%+0.33%Free Sign Up

All numbers in USD

Haemonetics Corporation Earnings Call Summary for Q1/2027

  • Haemonetics posted Q1 FY2027 adjusted EPS of $1.14 on revenue of $339M, beating estimates of $1.09 and $328.92M; shares fell 1.91% premarket.
  • Revenue rose 6% YoY with broad-based growth across MedSurg, Apheresis, and Interventional Technologies platforms; organic growth also up 6%.
  • Company raised FY2027 revenue guidance to 5-8% reported growth, reaffirmed 50-100 bps operating margin expansion target and 80% FCF conversion.
  • Gross margin declined 40 bps to 60.4% and operating margin fell 70 bps to 23.4% YoY, pressured by higher personnel and freight costs.
  • CEO Simon stated M&A is off the table; focus remains on executing product launches including Persona PLUS and VASCADE MVP XL while reducing leverage.
Last Updated: 2026-08-06, 09:12 a/m
Read Full Transcript

FAQ

What Is Haemonetics's Earnings Per Share (TTM)?

The Haemonetics EPS (TTM) is 2.07.

When Is The Next Haemonetics Earnings Date?

Haemonetics will release its next earnings report on Nov 05, 2026.

What Is Haemonetics’s Revenue Forecasts For Upcoming Quarters?

Haemonetics’s revenue forecast is 342.58M.

How Did Haemonetics React to the Company's Latest Earnings Report?

Haemonetics reported a +4.59% EPS surprise and a +3.06% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 5.07%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.